Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer

• Published in: Molecular cancer Vol. 10; no. 1; p. 19
• Main Authors: Satheesha, Sampoorna, Cookson, Victoria J, Coleman, Louise J, Ingram, Nicola, Madhok, Brijesh, Hanby, Andrew M, Suleman, Charlotte A B, Sabine, Vicky S, Macaskill, E Jane, Bartlett, John M S, Dixon, J Michael, McElwaine, Jim N, Hughes, Thomas A
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 14.02.2011; BioMed Central; BMC
• Subjects: 5' Untranslated Regions - genetics; Adaptor Proteins, Signal Transducing - metabolism; Breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Breast Neoplasms - surgery; Cancer; Cell Line, Tumor; Cell Proliferation - drug effects; Diagnosis; Drug resistance; Drug Screening Assays, Antitumor; Drug therapy; Eukaryotic Initiation Factor-4E - genetics; Eukaryotic Initiation Factor-4E - metabolism; Everolimus; Female; Gene Expression Regulation, Neoplastic - drug effects; Genes; Genes, Reporter; Genetic aspects; Humans; Kinases; Medical research; Phosphoproteins - metabolism; Phosphorylation - drug effects; Physiological aspects; Preoperative Care; Protein Biosynthesis - drug effects; Proteins; Sirolimus - analogs & derivatives; Sirolimus - pharmacology; Tissue Culture Techniques; TOR Serine-Threonine Kinases - antagonists & inhibitors; TOR Serine-Threonine Kinases - metabolism; United Kingdom

Inhibitors of the kinase mTOR, such as rapamycin and everolimus, have been used as cancer therapeutics with limited success since some tumours are resistant. Efforts to establish predictive markers to allow selection of patients with tumours likely to respond have centred on determining phosphorylat...